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Abstract  
 
Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss in older 
adults and impairs the ability to read, drive, and live independently and increases the risk for 
depression, falls, and earlier mortality.  Although new medical treatments have improved AMD’s 
prognosis, vision-related disability remains a major public health problem.  Improving Function 
in AMD (IF-AMD) is a two-group randomized, parallel design, controlled clinical trial that 
compares the efficacy of Problem-Solving Therapy (PST) with Supportive Therapy (ST) (an 
attention control treatment) to improve vision function in 240 patients with AMD.  PST and ST 
therapists deliver 6 one-hour respective treatment sessions to subjects in their homes over 2 
months.  Outcomes are assessed masked to treatment assignment at 3 months (main trial 
endpoint) and 6 months (maintenance effects).  The primary outcome is targeted vision function 
(TVF), which refers to specific vision-dependent functional goals that subjects highly value but 
find difficult to achieve.  TVF is an innovative outcome measure in that it is targeted and tailored 
to individual subjects yet is measured in a standardized way.  This paper describes the research 
methods, theoretical and clinical aspects of the study treatments, and the measures used to 
evaluate functional and psychiatric outcomes in this population. 
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Introduction  
 
Age-Related Macular Degeneration (AMD) is the leading cause of severe vision loss in older 
adults, with almost 2 million persons in the United States having advanced disease and over 7 
million having early signs. [1]  Aging of the population will double these numbers by 2020, 
dramatically increasing the prevalence of older adults who have lost the ability to read, drive, 
and live independently and who are at risk for depression, falls, and institutionalization. [2-7] 
Although the anti-vascular endothelial growth factor (anti-VEGF) antibodies ranibizumab and 
bevacizumab have greatly improved the prognosis of neovascular or “wet” AMD (there are no 
effective treatments for atrophic or “dry” AMD although certain vitamin preparations slow 
disease progression), many patients continue to have disabling vision impairment. [8,9]  Thus, 
AMD-related disability remains a major public health problem.  
 
To address that problem, we designed a study entitled, “Improving Function in AMD” (IF-AMD), 
which is a randomized, controlled clinical trial that compares the efficacy of Problem-Solving 
Therapy (PST) with Supportive Therapy (ST) to improve vision function in patients with AMD. 
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The study recruits 240 subjects:  120 will be randomized to receive 6 one-hour, in-home PST 
sessions, and 120 will be randomized to a control group who will receive ST in an identical 
treatment format.  PST is a psychological treatment that teaches patients to identify problems, 
generate alternative solutions, select the best solution, develop and conduct a plan, and 
evaluate whether the plan solves the problem.  ST is a structured, standardized, psychological 
treatment that controls for the nonspecific effects of attention.  The primary aims of the IF-AMD 
trial are to test the immediate (3-months) and longer term (6-months) efficacy of PST to improve 
the primary outcome of vision function.   
 
Vision function refers to vision-related abilities to perform daily living activities (e.g. reading 
recipes to prepare meals).  Our approach to measuring vision function combines both innovative 
(i.e., Targeted Vision Function) and widely used standard measures (i.e., National Eye Institute 
Vision Function Questionnaire (NEI VFQ). [9]  Targeted vision function (TVF) refers to specific 
vision-dependent functional goals that subjects highly value but find difficult to achieve.  As an 
outcome measure TVF is innovative and novel, as it recognizes that different people have 
unique vision function goals.  In this way, TVF is targeted and tailored yet measured in a 
standardized way in all subjects.  
 
The secondary outcomes of the IF-AMD trial are general- and vision-specific quality of life.  
Quality of life ratings add unique information over and above functional ability assessments and 
increase our ability to detect broader treatment effects.  We also plan to assess PST’s 
specificity by measuring subjects’ coping strategies, pre- and post-intervention, to determine 
whether increasing healthy coping strategies mediates PST’s effect on vision function over and 
above the nonspecific effects of attention.  We also plan an exploratory aim to examine whether 
improvement in vision function is moderated by baseline depression status and type of AMD 
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(wet or dry) given that previous research suggests that these characteristics may differentially 
affect treatment outcomes. 
 
Study Design 
 
This trial recruits 240 patients with AMD from the retina clinics associated with the Wills Eye 
Institute (WEI) in Philadelphia, PA and randomizes subjects to PST or ST in a 1:1 allocation 
ratio.   Randomization is stratified based on severity of AMD (visual acuity better vs. worse than 
20/100 in the better eye) as treatment response may vary by severity of vision loss.  A random 
numbers table and serially numbered, sealed, opaque envelopes containing the treatment 
allocations are used to assign subjects to the treatment groups within each stratum.  The 
randomization schedule is based on a permuted random block design to ensure balance 
between treatment groups on time of subject enrollment.  When patients register for their retina 
clinic visits they have the opportunity to provide written permission to be contacted for possible 
participation in clinical research.  Each week a research assistant reviews the clinical records of 
patients who provided permission to identify those who met eligibility criteria.  We then confirm 
the AMD diagnosis with each patient’s ophthalmologist, obtain his/her permission to contact the 
patient, and mail introductory letters to patients signed by the ophthalmologist.  We then 
telephone patients one week later to explain the study, confirm their willingness and eligibility to 
participate, and schedule an in-home visit within 2 weeks to obtain written informed consent and 
conduct the baseline assessment.  This method of case ascertainment is objective and 
verifiable, and although subjects self-select for study participation, recruitment avoids relying on 
ophthalmologists to identify eligible cases and minimizes other selection biases or missed 
cases.   During the informed consent process we state that the study’s purpose is to compare 
the efficacy of PST and ST, and that both interventions may improve a person’s ability to 
function with macular degeneration.  We indicate that PST emphasizes problem solving skills 
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and that ST emphasizes support and attention to the problems that vision loss causes.  We 
furthermore state that neither PST nor ST will improve vision.  Jefferson’s Institutional Review 
Board approved this approach to contacting and consenting patients for research participation.  
Following randomization, trained PST and ST therapists deliver 6 one-hour treatment sessions, 
respectively, to subjects in their homes over 2 months.  Outcome assessments masked to 
treatment assignment occur at 3 and 6 months post-randomization.  Figure 1 depicts the 
schedule of study activities. 
 
The study inclusion criteria are: 1) age 65 years or older; 2) bilateral AMD (neovascular and/or 
dry); 3) visual acuity between 20/70 and 20/400 [inclusive; (best corrected)] in the better-seeing 
eye, and no lower acuity limit in the fellow eye; and 4) moderate difficulty in at least one valued 
vision-function goal.  The exclusion criteria are: 1) presence of uncontrolled glaucoma, diabetic 
retinopathy, or planned cataract surgery within 6 months; 2) cognitive impairment on an 
abbreviated version of the Mini-Mental Status Examination (MMblind) that omits vision-
dependent items [10]; 3) presence of life-threatening illness; and 4) residence in a skilled 
nursing facility.  
 
We chose patients with bilateral disease of this severity because they are more disabled than 
patients with unilateral AMD or those with less severe vision loss.  This is a conservative 
criterion given West et al’s data showing that binocular visual acuity worse than 20/40 adversely 
affects vision function and impairs reading in 90% of individuals. [11]  We exclude cognitively 
impaired patients because their cognitive deficits preclude learning new problem-solving skills.  
Taken together, these eligibility criteria generate a sample of patients with AMD who are at high 
risk for disability, who are likely to benefit from PST, and who are easily recognizable in clinical 
practice. 
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Conceptual Model 
 
The theoretical basis for the IF-AMD Trial is the Disablement Process Model. [12]  This is a 
sociomedical model of disability which describes how medical diseases affect functioning in 
specific body systems and can lead to disability.  Verbrugge et al incorporated psychosocial 
factors in the model which led to their inclusion in the most recent World Health Organization’s 
(WHO) International Classification of Functioning, Disability and Health. [13] The WHO model 
describes function and disability as part of a “complex relationship between health conditions 
and contextual (i.e. environmental and personal) factors” and explains how two patients with the 
same disease, of equal severity, can function quite differently from one another. [14]    
 
PST acts on the disablement process model to improve targeted vision function in 3 ways.  
First, it may reduce the visual demands of a task by helping patients to devise compensatory 
approaches.  Second, PST may reduce depressive symptoms, thereby interrupting the 
downward spiral of increasingly worsening function and depression that can occur.  Third, PST 
encourages behavioral activation, maintains social engagement, and may result in greater use 
of low vision devices and services, which may further reduce task difficulty. 
 
Study Treatments 
 
1. Problem-Solving Therapy (PST):  PST is a brief, psychological treatment that teaches 
problem-solving skills for a variety of conditions (e.g., depression, osteoarthritis, chronic pain, 
obesity). [15-21]  We previously demonstrated the efficacy of PST as a short-term treatment to 
prevent depression in patients with AMD. [22]  Its use in AMD recognizes that vision loss is 
disabling and that enhancing problem-solving skills may reduce disability.  PST also helps 
patients to recognize the realistic limitations of their visual abilities and to find alternative 
 10 
approaches so that valued activities can still be performed (e.g. using public transportation as 
an alternative to driving, enabling a patient to continue to travel independently).   Thus, PST 
attempts to reduce task difficulty of valued activities by teaching commonsense, problem-solving 
skills in a structured way.   
 
The PST therapist and subject begin the treatment process by discussing the subject’s 
difficulties with specific tasks (e.g., writing checks) that underlie a vision-dependent activity (e.g., 
managing personal finances).  Then, the therapist teaches the problem-solving steps to help the 
subject devise new ways to reduce task difficulty.  The 7 steps are:    
 
a. clarifying the problems associated with the task 
b. establishing a realistic goal toward improvement of task performance 
c. generating multiple solution alternatives 
d. implementing decision-making guidelines 
e. choosing the preferred solution(s) 
f. implementing the preferred solutions(s) and 
g. evaluating the outcome 
 
The PST therapist discusses the Target Vision Function activities that a subject identified at 
baseline.  The subject selects one vision function activity to address first, and then identifies the 
problems with performing the tasks that make it difficult to achieve.  The goal must be one that 
can be realistically achieved between sessions and that the subject can exert some control 
over.  This involves breaking down large problems into more manageable parts or reframing the 
problem so that feasible solutions can be generated.   For example, if the activity is meal 
preparation, the problematic tasks may be measuring ingredients and using the stove.  The PST 
therapist guides the subject through the problem-solving steps to devise compensatory 
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strategies to improve performance of these tasks.  In this context, the PST therapist may review 
a list (printed in large font) of potentially helpful rehabilitative services and devices.  Subjects 
may refer to the list when brainstorming possible solutions to their problems.   
 
A key modification to the brainstorming step of PST was the integration of the Person, 
Environment, Occupation Model (PEO) of occupational therapy.  [23] In the PEO model the term 
"occupation" refers to “valued activities.”  The PEO model suggests three potentially 
complementary courses of action in response to impaired function.  When faced with a 
participation restriction the individual can: (1) change something about their personal skills and 
capabilities, (2) change the environment in which the activity is performed, or (3) change the 
nature of the activity itself.  The therapist encourages the subject to think in terms of these 
themes when generating solutions.  However, the PST therapist does not give direct advice; 
instead the therapist asks subjects to use problem-solving skills to find ways to obtain and/or 
implement a service or device.  Once one activity has been addressed, the subject then 
addresses additional activities.  The number of activities that are ultimately addressed will 
depend on the subject, his/her success or difficulty implementing solutions, and the complexity 
of the problem.  The aim is to have subjects incorporate the problem-solving method of 
reasoning as a routine, often recruited approach to solving future as well as current function-
related problems.   
 
2.  Supportive Therapy (ST) 
  
We are testing PST’s efficacy by comparing it to ST, which is a similarly structured, 
standardized, control psychological treatment that controls for nonspecific treatment effects. [24-
26] ST resembles PST in all ways but for PST’s problem-solving skills training.  Both are fully 
manualized, similar in dose and intensity of attention (i.e. number and duration of sessions), 
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equally credible, and delivered by therapists trained in both treatments to minimize therapist 
effects.  ST is nondirective, supportive, and facilitates personal expression and conveys 
empathy, respect, and optimism (i.e. a general sense that things can get better).  The ST 
therapist informs a subject that ST’s purpose is to explore the impact of vision loss on his or her 
life. The goals are to facilitate and deepen knowledge about the subject’s life situation and its 
relationship to growing older and all of the issues associated with that such as illness, disability, 
retirement, social isolation and, particularly, vision loss.  This portion of therapy is presented as 
an exploration process that might be helpful for increasing self-confidence.  Therapists create an 
accepting, non-judgmental, empathic environment, by using supportive statements, reflective 
listening, and empathic communications.  In contrast to PST sessions, there is no discussion of 
vision function goals, problem solving, or low vision rehabilitative strategies.  Unlike PST, ST 
contains no active elements beyond its nonspecific components, has no long-lasting treatment 
effects, and no theoretical basis to support an effect on vision function.  In this way ST is a sham 
or control treatment.  Although ST reduces distress for the time that treatment is delivered, its 
effects are thought to be transient and not associated with meaningful functional improvement.   
 
Sample Size Calculation 
 
We based the sample size calculation on the following parameters:  one primary outcome (i.e., 
Targeted Vision Function); and treatment effect sizes (ES) observed in other trials of PST and 
ST.  A recent meta-analysis of PST reported ESs ranging from .34 to .83; on this basis we 
powered the study to detect a medium ES of 0.40. [15]  To attain 80% power for a 2-sided 
alternative hypothesis using a F-test to compare the 2 treatment groups at 3 months, we 
required 200 subjects (100 per group) to detect an effect size of .4.  We over-sampled by 20% 
to account for attrition, bringing the total sample size to 240.  
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Masking 
 
Psychotherapy trials differ from most other clinical trials in medicine in that double-blind 
administration of treatments is impossible:  therapists are aware of what treatment they deliver 
as are the subjects.  Recognizing this, procedures have been developed to ensure structural 
equivalence of treatments and to assess and maintain treatment fidelity and differentiability.  A 
research nurse who is masked to treatment assignment obtains all outcome data during in-
home interviews.  The nurse instructs subjects to reveal nothing about the treatments they may 
have received.  Despite careful precaution, breaches in masking occur that may introduce 
treatment-related biases.  [27, 28]  We require that central data collection, measurement, and 
data entry procedures are made by persons masked to treatment assignment; only the project 
director, statistician, and therapists are aware of treatment assignment.  Prior to all outcome 
assessments, the purpose and importance of masked treatment assignment are discussed with 
subjects. 
 
Fidelity, Supervision, and Adherence 
 
The therapists for this study are trained to deliver both PST and ST.  Having each therapist 
deliver both forms of treatment (rather than having separate therapists for each treatment) 
reduces variance due to therapist effects.  In this regard, it is critically important to have both 
therapists closely follow the PST and ST treatment manuals.  To maintain their objectivity, we 
did not inform them of the study hypotheses or the nature of the outcome measures. 
 
Both PST and ST are manual driven treatments; thus training concentrates on properly adhering 
to the principles and activities outlined in the manual.  The training program consists of 
workshops, review and discussion of the relevant treatment manuals, and supervision of 5 
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training cases.  Therapists must meet satisfactory levels of competence before starting the 
treatment trial.  All treatment sessions are audio-taped during the study and 30% of subjects are 
randomly selected for treatment fidelity ratings to control for treatment “drift.”  To assess 
subjects’ adherence to PST, the therapists rate whether PST subjects understand and apply 
PST principles; whether subjects comply with homework; and whether requisite problem-solving 
tasks are accomplished.   
 
 
 
 
Primary Outcome Measure 
 
1.  Vision Function:  There is no single, universally accepted measure or methodology to 
measure vision function.  Although instruments such as the National Eye Institute Vision 
Function Questionnaire (NEI-VFQ), the Activities Inventory (AI), and the Veterans Affairs Low 
Vision Visual Functioning Questionnaire (VA LV VFQ-48) measure multiple aspects of vision 
function, few studies have evaluated their sensitivity to psychosocial interventions.  [9, 29-31] 
Because these instruments measure several diverse dimensions of vision loss (i.e., the NEI-
VFQ assesses difficulty with daily activities, social functioning, general health and vision, and 
quality of life), they may be unable to detect specific intervention effects.  This may be especially 
true when the most important outcome is an improvement in a personally valued goal.  
Improvement on just one goal may enhance life quality tremendously but may not be reflected 
as a statistically significant change on a multi-dimensional rating scale.  Furthermore, because 
vision goals and vision deficits vary from person to person, change in total scale scores may be 
less informative than change in a more targeted outcome. 
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To address this issue, we are using a targeted outcome measurement approach, which employs 
a standardized method to identify and quantify specific problems for outcome assessment. [30]  
A number of studies have demonstrated this approach’s reliability, validity and practicality, 
showing that it can be more sensitive to treatment effects than multi-dimensional, multi-
symptom measures.  [32-34]  Using such an approach, we devised a measure, Targeted Vision 
Function (TVF), to serve as the primary outcome of the IF-AMD trial.  As an outcome measure, 
TVF pinpoints and evaluates change in the vision-function goals that subjects consider most 
important and has the face validity, clinical relevance and flexibility to convey meaningful 
change in response to rehabilitative interventions.  To derive the TVF measure, at the baseline 
assessment, prior to randomization, subjects complete the Activities Inventory and identify up to 
4 vision function goals that they highly value ( rated as “important” or “very important”) but find 
difficult to achieve.  They then rate the difficulty of each goal on a scale from 0 to 4 (not difficult, 
to impossible).  The average TVF score is the sum of the difficulty ratings of the (up to) 4 goals 
divided by the number of goals (from 1 to 4).  Higher average scores indicate greater disability.  
At each outcome assessment (efficacy at 3 months; long-term benefit at 6 months), subjects 
again rate the difficulty of the same targeted goals and the average TVF score is calculated.  
For example, at baseline a subject may rate the goal of cooking as moderately difficult (score = 
2) and rates paying bills as very difficult (score = 3).  The subject’s average TVF score at 
baseline is then = 2.5.  At 3 months, PST may have reduced the difficulty of both goals by one 
level (2 to 1 for cooking, and 3 to 2 for paying bills) such that the average TVF score is 1.5.  
Thus, possible average TVF scores at 3 months can range from 0 (no difficulty on any goal) to 4 
(severe difficulty on 4 goals).  While this may seem like a narrow range, actual scores are likely 
to be decimals, such that the variability of scores is considerably larger.  
 
At the study endpoints, the mean differences from baseline in the average TVF scores in the 
two treatment groups are compared after adjusting for baseline scores.  This approach allows 
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that subjects may vary in the number of TVF goals they selected at baseline.  The primary 
treatment hypothesis is that PST-subjects will report less difficulty with TVF goals at 3 months 
compared to ST-controls; this will be reflected in lower average TVF scores in between-group 
and within-group comparisons. 
 
Secondary Outcome Measures: 
 
1.  Activities Inventory (AI):  The AI is a structured vision function questionnaire that asks 
patients to rate the value and difficulty of 48 vision function goals (e.g., daily meal preparation) 
and the tasks (e.g., seeing stove settings) that are required to achieve them. [30,31]  The goals 
are nested under 3 main Objectives (e.g., Independent Daily Living, Social Interactions, and 
Recreation).  If a goal is important (range not important “0” to very important “4”), the subject 
rates its “difficulty” [on a scale of 0 (not difficult) to 4 (impossible)].   The AI provides the 
standardized method necessary to identify the TVF goals described above in clear, specific, and 
operational terms, and guides subjects through a process of inquiries to identify their goals.  
This works especially well in AMD because the universe of possible vision function goals, 
although theoretically unlimited, in practice is finite and definable using the AI.  Also, the AI’s 
extensive development and validation in large populations of older visually impaired people 
avoids the possibility that subjects may define a problem that cannot be addressed in treatment.   
 
2.  NEI VFQ-25 plus Supplement:  The NEI VFQ-25 consists of 25 items and a supplement of 
14 additional items, derived from the original 52-item NEI VFQ. [9]  This instrument measures 
both self-reported vision function and vision-related quality of life (QoL).  Of the 39 items, 6 ask 
patients to grade their general health and vision, 20 rate difficulties with activities, and 13 
assess the severity of problems associated with vision loss (and include the QoL questions).  
The items on activity difficulties are rated from 1 to 6, with responses indicating increasing levels 
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of difficulty.  The QoL questions assess vision-specific social functioning, vision-specific mental 
health, vision-specific role difficulties, and dependency due to vision.  The instrument creates 11 
subscale scores and an overall score.  The NEI VFQ-25 can be accessed at 
http://www.rand.org/health/surveys_tools/vfq/. 
     
3.  Quality of Life (QoL):  We will investigate whether PST influences quality of life using the 
vision-related quality of life (QoL) items of the NEI-VFQ-25 plus Supplement. [9]  A number of 
research reports indicate that disease-specific measures perform better than generic measures 
of QoL.  For example, Scott et al showed that vision-targeted questionnaires better demonstrate 
associations between vision and QoL and are more sensitive than general health-related QoL 
questionnaires to score changes in response to low vision services. [35]    Nevertheless, we 
believe it is important to include a general QoL measure to compare our outcomes with other 
non-ophthalmologic patient populations.  Thus, we will also measure general QoL at baseline 
and at months 3 and 6 using the 6-item Medical Outcome Study (MOS-6) survey, which 
assesses physical, role, social, and psychological functioning, as well as current health 
perceptions and physical pain. [36] Although we hypothesize that PST will improve vision-
related QoL, we anticipate benefits in other areas of life as well.   
 
Other Measures  
 
Personal Characteristics:  These include age, sex, race, marital status, living arrangements, 
education, and income. 
 
Vision Status:  We have devised a standardized battery of vision tests which we administer in 
subjects' homes at baseline and months 3 and 6.  This approach standardizes vision 
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assessments by setting and examiner and includes the assessment of distance and near visual 
acuity, contrast sensitivity, and the size and location of central scotomas. 
 
Physical Health Status:  To assess physical status we obtain the Chronic Disease Score, which 
provides an objective measure of medical comorbidity based on a weighted sum of medications 
taken for chronic illness, and the Multilevel Assessment Inventory Health Conditions Check List, 
which lists specific acute and chronic conditions. [37, 38] 
  
Depression:  We will use the Patient Health Questionnaire-9, which is a diagnostic instrument 
that generates criteria-based diagnoses of depression and a continuous measure of depression 
severity. [39] 
 
Behavior Activation for Depression Scale (BADS):  Subjects in both treatment groups complete 
the BAS at baseline and at months 3 and 6 to assess change in healthy versus unhealthy 
coping strategies.  The BADS, which consists of 26 items rated on a 7-point scale, yields 4 
subscale scores:  1) the Activation scale measures adherence to goal directed planned activities 
(e.g., following through on a plan to try audio books to circumvent reading difficulties); 2) 
Avoidance/Rumination assesses avoidance of negative states and the tendency to think about 
problems but not problem solve solutions (e.g., continual thinking about vision loss but 
unwillingness to try magnifiers);  3) Work/School Impairment refers to an unwillingness to fulfill 
necessary responsibilities and obligations (e.g., not paying bills because it is too difficult); and 4) 
Social Impairment measures social isolation (e.g., avoiding social situations because it is hard 
to see faces). [40]  Together these subscales provide a quantifiable process measure to link 
treatment assignment to outcomes and increase our ability to detect specific treatment effects.   
 
Data Analyses 
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The observations to be used for primary and secondary outcome measures take the form of 
ordinal rating scales or dichotomous indicator scores.  The items to be scored in the TVF are 
subject-generated; the other instruments require that the same fixed set of items be rated by all 
subjects.  Summary scores are generated for the instruments with fixed sets of items by 
rescaling averages of response rank scores across items in the set.  These summary scores 
necessarily have a ceiling and a floor, which limit the sensitivity and interpretability of change 
scores to treatment effects.   To correct for ceiling and floor effects, we will linearize rating scale 
summary scores using a logit transform. [41]   
The TVF consists of activity goals drawn from the AI.  The subject’s rating of goal importance 
serves as a filter to determine whether the goal will be included in the subject’s personal set.  
The subject’s rating of goal difficulty serves two functions: 1) it acts as a filter to determine which 
goals that pass the importance test will be included in the subject’s personal set and,  2) it 
provides an ordinal magnitude estimate of the latent variable that is the outcome measure.  
Each activity goal in the AI requires a minimum level of visual ability to be achieved with a 
criterion level of ease.  The minimum required visual ability for each goal has been estimated 
from difficulty ratings by a large sample of the low vision population.  [42, 43] Theoretically, the 
difficulty rating corresponds to the subject’s estimate of the magnitude of the difference between 
that subject’s visual ability and the visual ability required by the goal, i.e., functional reserve. A 
positive outcome means that PST increases functional reserve for one or more of the subject’s 
goals.  Thus, we expect to see an increase in average functional reserve across goals if PST is 
effective.  However, the intervals between difficulty response categories are not necessarily 
equal; therefore, we cannot simply use averages of the response rank scores.  Based on Rasch 
analysis of AI goal difficulty ratings for a large sample of the low vision population, we have 
estimates of average functional reserve for each difficulty response category, which is a linear 
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interval-scaled measure. [42, 43]  We will transform individual TVF goal difficulty ratings to low 
vision population-based functional reserve values and average across each subject’s goals. The 
change in average functional reserve from baseline to post-treatment is the primary outcome 
measure. 
To test the efficacy of PST to improve TVF functional reserve measures at 3 months, we will use 
an ANCOVA in which group differences (PST vs. ST) in 3-month average TVF scores will be 
examined, adjusting for baseline TVF measures.  The stratification variable [visual acuity 
between 20/70 and 20/100 (inclusive) vs. worse than 20/100 in the better eye)] will also be a 
covariate, as will any demographic or clinical characteristics that are significantly different 
between the two study groups.  We will also conduct subsidiary analyses that will examine 
treatment group effects on total AI measures and the NEI-VFQ vision function difficulty 
measures at 3 months estimated from Rasch analysis. 44]  To evaluate the long-term effects of 
PST at 6-months, we will use the same strategy as above except that the dependent variable 
will be TVF, AI, or NEI VFQ measures, respectively at 6-months. 
To determine PST’s impact on vision-related quality-of-life at 3 months, we will use a 
MANCOVA in which the dependent variables will be the following 4 NEI-VFQ logit-
transformedsubscales assessed at 3 months:  1) vision-specific mental health; 2) vision-specific 
role functioning; 3) dependency due to vision loss; and 4) vision-specific social functioning.  We 
will conduct a parallel analysis using total MOS scores to examine the impact on general quality 
of life.  We will conduct parallel analyses using 6 month data.  To determine whether the 
mechanism linking PST to improved TVF involves changes in coping strategies, we will use 
Baron and Kenny’s 3-step approach to test for mediation effects. [45]  
  
Conclusion 
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Severe vision loss and disability are frequent consequences of AMD.  Although anti-VEGF 
treatments can improve and/or stabilize vision, many patients continue to have high levels of 
disability and depression. [46]   In fact, many patients experience vision loss, depression, and 
disability as a single syndrome, with each element amplifying and perpetuating the adverse 
effects of the others.  Thus, a brief, easy to understand, behavioral intervention that improves 
vision function may also reduce the risk of depression.  
 
To improve vision function, we are using PST, which teaches patients new skills to solve vision 
function problems and thereby to preserve their ability to pursue valued activities.  AMD 
provides an ideal model to test the problem solving approach because it is common, affects 
men and women equally, is quantifiable in terms of severity, has no overlap of symptoms with 
depression (which confounds assessments of disability in osteoarthritis, stroke, and cancer) and 
produces disability within a short time period, making it an efficient disease model.  If the trial is 
successful, its results may well generalize to other chronic, disabling disorders, especially those 
that impair vision (e.g. diabetic retinopathy, glaucoma).  The clinical and public health 
significance of the IF-AMD trial are clear: the disability of AMD will become more prevalent, 
costly, and burdensome to patients, families, and ophthalmologists as the population ages. [2, 3]  
This makes devising and testing practical interventions to improve vision function a national 
priority. 
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Figure 1.  Schedule of Study Activities 
 
 
 Study Month 
 0      3       6 
Baseline  Assessment X              
Intervention visits  
(PST or ST) 
X X X X X X         
3-month assessment       X        
6-month assessment              X 
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